At Pinnacle Medicines, our vision is to transform patients' lives through oral peptide therapeutics.
Our team brings deep experience advancing first-in-class therapeutics from discovery through clinical development. Our pipeline is initially focused on developing oral peptides against targets validated by blockbuster biologic drugs. By creating oral alternatives to injectable therapies, we aim to broaden treatment access and improve the patient experience.
Beyond this initial focus, we aim to expand the application of macrocyclic peptides across a wider range of therapeutic areas and targets, including both intra- and extracellular targets, opening new possibilities for diseases where other modalities have historically fallen short.
Our vision is implemented by our proprietary discovery platform that integrates established physics with emerging AI methodologies. We believe peptides are uniquely positioned to gain from the AI revolution, allowing us to navigate the vast chemical and conformational space to de novo design functional binders as well as optimize hits into safe, effective therapeutics.
Leveraging our integrated presence in the United States and China, we significantly accelerate the discovery and development of these molecules, translating innovation efficiently from concept to patients.
